Antithrombin activity of an algal polysaccharide.


In an effort to reduce the risks of a possible iatrogenic transmission of bovine spongiform encephalitis (BSE) through the use of bovine-derived medicinal products, we patented in the USA in 1999 a polysaccharide from brown algae, endowed with interesting pharmacological activities: (a) concentration-dependent inhibition of thromboplastin or cephalin-kaolin-induced thrombin generation from platelets, (b) concentration-dependent inhibition of thrombin-induced platelet aggregation, (c) thrombin has hypotensive effect, which was blunted and zeroed by our fucansulfate in a dose-dependent way, (d) when aortae are stimulated with thrombin, they become stickier for polymorphonucleated leukocytes (PMNs); our fucansulfate decreased concentration-dependently, PMNs sticking to autologous rabbit aortae, (e) dose-dependent inhibition of thrombin-induced thrombosis. All the above data suggest that our fucansulfate could be a heparin substitute endowed with antithrombotic and anti-inflammatory activities, devoid or the problems caused to heparin by its animal origin, i.e., possible prion protein contamination.

Citations per Year

119 Citations

Semantic Scholar estimates that this publication has 119 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Trento2001AntithrombinAO, title={Antithrombin activity of an algal polysaccharide.}, author={Fabio Trento and Franco Cattaneo and Rodolfo Pescador and Roberto Porta and Laura I Ferro}, journal={Thrombosis research}, year={2001}, volume={102 5}, pages={457-65} }